Literature DB >> 9617063

Study of trichomoniasis among Egyptian male patients.

S F el Seoud1, M M Abbas, F S Habib.   

Abstract

In the present study, Trichomonas vaginalis was diagnosed in 28.8% male patients with urethral discharge and in 8.2% suffering from impotence and infertility. Diagnosis was based on examination of urethral discharge, urine, semen and prostatic massage fluid by wet mount, stained films and culture inoculation. Diamond's culture proved to be the method of choice.

Entities:  

Mesh:

Year:  1998        PMID: 9617063

Source DB:  PubMed          Journal:  J Egypt Soc Parasitol        ISSN: 1110-0583


  5 in total

1.  Trichomonas vaginalis epidemiology: parameterising and analysing a model of treatment interventions.

Authors:  F J Bowden; G P Garnett
Journal:  Sex Transm Infect       Date:  2000-08       Impact factor: 3.519

2.  Improved diagnosis of Trichomonas vaginalis infection by PCR using vaginal swabs and urine specimens compared to diagnosis by wet mount microscopy, culture, and fluorescent staining.

Authors:  C van Der Schee; A van Belkum; L Zwijgers; E van Der Brugge; E L O'neill; A Luijendijk; T van Rijsoort-Vos; W I van Der Meijden; H Verbrugh; H J Sluiters
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

Review 3.  Human parasitic protozoan infection to infertility: a systematic review.

Authors:  Malihe Nourollahpour Shiadeh; Maryam Niyyati; Shirzad Fallahi; Ali Rostami
Journal:  Parasitol Res       Date:  2015-11-16       Impact factor: 2.289

4.  Trichomoniasis: clinical manifestations, diagnosis and management.

Authors:  H Swygard; A C Seña; M M Hobbs; M S Cohen
Journal:  Sex Transm Infect       Date:  2004-04       Impact factor: 3.519

5.  Trichomonas vaginalis serostatus and prostate cancer risk in Egypt: a case-control study.

Authors:  Nora E Saleh; Samar M Alhusseiny; Wafaa M El-Zayady; Engy M Aboelnaga; Wafaa N El-Beshbishi; Yasser M Saleh; Hala S Abou-ElWafa; Samar N El-Beshbishi
Journal:  Parasitol Res       Date:  2020-11-07       Impact factor: 2.289

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.